Induction of mixed chimerism depletes pre-existing and de novo-developed autoreactive B cells in autoimmune NOD mice

Diabetes

Volumn 63, Issue 6, 2014, Pages 2051-2062

  Racine, Jeremy J ^a,b   Wang, Miao ^b   Zhang, Mingfeng ^b   Zeng, Defu ^a,b  

^a Irell and Manella Graduate School of Biological Sciences   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; INSULIN ANTIBODY;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNE DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; KINETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SPLEEN CELL; T CELL DEPLETION; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CHIMERISM; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED NOD; SPLEEN; TRANSPLANTATION CHIMERA; TRANSPLANTATION TOLERANCE;

EID: 84901362128     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1532     Document Type: Article

References (49)

1. Herold KC, Bluestone JA. Type 1 diabetes immunotherapy: is the glass half empty or half full? Sci Transl Med 2011;3:fs1
2. Bonifacio E, Atkinson M, Eisenbarth G, et al. International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes 2001;50:2451-2458
3. Serreze DV, Chapman HD, Varnum DS, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J Exp Med 1996;184:2049- 2053
4. Akashi T, Nagafuchi S, Anzai K, et al. Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in nonobese diabetic mice. Int Immunol 1997;9:1159-1164
5. Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 1997;46:941-946
6. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 1998;161: 3912-3918
7. Falcone M, Lee J, Patstone G, Yeung B, Sarvetnick N. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol 1998;161:1163- 1168
8. Charlton B, Zhang MD, Slattery RM. B lymphocytes not required for progression from insulitis to diabetes in non-obese diabetic mice. Immunol Cell Biol 2001;79:597-601
9. Kendall PL, Moore DJ, Hulbert C, Hoek KL, Khan WN, Thomas JW. Reduced diabetes in btk-deficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene. J Immunol 2009;183:6403- 6412
10. Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117:3857-3867 (Pubitemid 350224095)
11. Xiu Y, Wong CP, Bouaziz JD, et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype- specific differences in Fc gamma R effector functions. J Immunol 2008;180: 2863-2875
12. Fiorina P, Vergani A, Dada S, et al. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 2008;57:3013-3024
13. Serreze DV, Chapman HD, Niens M, et al. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes 2011;60:2914-2921
14. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
15. Pescovitz MD, Greenbaum CJ, Bundy B, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 2014;37:453-459
16. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769
17. Chatenoud L. Therapeutic targeting of B cells and T cells in autoimmune diabetes: is it a solution? Diabetes 2013;62:2659-2661
18. Hu C, Ding H, Zhang X, Wong FS, Wen L. Combination treatment with anti- CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes. Diabetes 2013;62:2849-2858
19. Li N, Chen Y, He W, et al. Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI. Blood 2009;113:953-962
20. Li N, Zhao D, Kirschbaum M, et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci USA 2008;105:4796-4801 (Pubitemid 351753826)
21. Liang Y, Huang T, Zhang C, et al. Donor CD8+ T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb. Blood 2005;105:2180-2188 (Pubitemid 40731811)
22. Racine J, Wang M, Zhang C, et al. Induction of mixed chimerism with MHC-mismatched but not matched bone marrow transplants results in thymic deletion of host-type autoreactive T-cells in NOD mice. Diabetes 2011;60: 555-564
23. Wang M, Racine JJ, Song X, et al. Mixed chimerism and growth factors augment beta cell regeneration and reverse late-stage type 1 diabetes. Sci Transl Med 2012;4:133ra59
24. Zhang C, Lou J, Li N, et al. Donor CD8+ T cells mediate graft-versusleukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody. J Immunol 2007;178: 838-850 (Pubitemid 46095156)
25. Zhang C, Todorov I, Lin CL, et al. Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. Proc Natl Acad Sci USA 2007;104:2337-2342 (Pubitemid 46391398)
26. Zhang C, Wang M, Racine JJ, et al. Induction of chimerism permits lowdose islet grafts in the liver or pancreas to reverse refractory autoimmune diabetes. Diabetes 2010;59:2228-2236
27. Li X, Deng R, He W, et al. Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease. J Immunol 2012;188:724-734
28. Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009;114:3101-3112
29. Yi T, Zhao D, Lin CL, et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 2008;112: 2101-2110
30. Young JS, Wu T, Chen Y, et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol 2012;189:222-233
31. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107:2993-3001
32. Zhao D, Zhang C, Yi T, et al. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 2008;112: 2129-2138
33. Culton DA, O'Conner BP, Conway KL, et al. Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J Immunol 2006;176: 790-802 (Pubitemid 43099675)
34. Tung JW, Mrazek MD, Yang Y, Herzenberg LA, Herzenberg LA. Phenotypically distinct B cell development pathways map to the three B cell lineages in the mouse. Proc Natl Acad Sci USA 2006;103:6293-6298
35. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991;173:1213-1225
36. Hoek KL, Carlesso G, Clark ES, Khan WN. Absence of mature peripheral B cell populations in mice with concomitant defects in B cell receptor and BAFF-R signaling. J Immunol 2009;183:5630-5643
37. Silveira PA, Dombrowsky J, Johnson E, Chapman HD, Nemazee D, Serreze DV. B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J Immunol 2004;172:5086-5094 (Pubitemid 38456437)
38. Giltiay NV, Chappell CP, Sun X, et al. Overexpression of TLR7 promotes cellintrinsic expansion and autoantibody production by transitional T1 B cells. J Exp Med 2013;210:2773-2789
39. Meyer-Bahlburg A, Andrews SF, Yu KO, Porcelli SA, Rawlings DJ. Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J Exp Med 2008;205:155-168 (Pubitemid 351185723)
40. Quinn WJ 3rd, Noorchashm N, Crowley JE, et al. Cutting edge: impaired transitional B cell production and selection in the nonobese diabetic mouse. J Immunol 2006;176:7159-7164 (Pubitemid 43849016)
41. Acevedo-Suárez CA, Hulbert C, Woodward EJ, Thomas JW. Uncoupling of anergy from developmental arrest in anti-insulin B cells supports the development of autoimmune diabetes. J Immunol 2005;174:827-833 (Pubitemid 40094278)
42. Wu T, Young JS, Johnston H, et al. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells. J Immunol 2013;191:488-499
43. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-798 (Pubitemid 38757447)
44. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigenengaged B cells due to increased dependence on BAFF. Immunity 2004;20:441- 453 (Pubitemid 38482122)
45. Rowland SL, Leahy KF, Halverson R, Torres RM, Pelanda R. BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol 2010;185:4570-4581
46. Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 2002;32:2004-2010 (Pubitemid 34814557)
47. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-2114 (Pubitemid 32848063)
48. Nikbakht N, Migone TS, Ward CP, Manser T. Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments. J Immunol 2011;187:37-46
49. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994; 371:389-395 (Pubitemid 24302553)